普洛药业7月15日在互动平台上表示,公司下半年订单整体保持相对平稳态势,其中CDMO订单增速较快,API业务处于新项目和新产能爬坡期,制剂业务也正处于快速增加ANDA阶段。
普洛药业7月15日在互动平台上表示,公司下半年订单整体保持相对平稳态势,其中CDMO订单增速较快,API业务处于新项目和新产能爬坡期,制剂业务也正处于快速增加ANDA阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.